Association of DS after 2 cycles of eBEACOPP with baseline characteristics
| . | N= . | DS 1-2 (%) . | DS 3 (%) . | DS 4 (%) . | Univariate P, DS 3-4 vs 1-2 . | Multivariate P, DS 3-4 vs 1-2* . | Univariate P, DS 4 vs 1-3 . | Multivariate P, DS 4 vs 1-3* . |
|---|---|---|---|---|---|---|---|---|
| Age at registration | ||||||||
| 18-44 y | 1535 | 760 (50) | 390 (25) | 385 (25) | .0002 | .02 | .05 | |
| 45-60 y | 410 | 245 (60) | 81 (20) | 84 (20) | ||||
| Sex | ||||||||
| Female | 761 | 376 (49) | 197 (26) | 188 (25) | .1 | .6 | ||
| Male | 1184 | 629 (53) | 274 (23) | 281 (24) | ||||
| Performance status | ||||||||
| ECOG = 0 | 1151 | 633 (55) | 268 (23) | 250 (22) | .0004 | .9 | .004 | |
| ECOG > 0 | 794 | 372 (47) | 203 (26) | 219 (28) | ||||
| Clinical stage | ||||||||
| II | 282 | 82 (29) | 102 (36) | 98 (35) | <.0001 | .5 | <.0001 | .1 |
| III | 955 | 565 (59) | 215 (23) | 175 (18) | ||||
| IV | 708 | 358 (51) | 154 (22) | 196 (28) | ||||
| B symptoms | ||||||||
| No | 704 | 431 (61) | 149 (21) | 124 (18) | <.0001 | .3 | <.0001 | .2 |
| Yes | 1241 | 574 (46) | 322 (26) | 345 (28) | ||||
| Large mediastinal mass† | ||||||||
| No | 1383 | 838 (61) | 277 (20) | 268 (19) | <.0001 | <.0001 | <.0001 | <.0001 |
| Yes | 561 | 167 (30) | 194 (35) | 200 (36) | ||||
| Extranodal involvement | ||||||||
| No | 1566 | 865 (55) | 370 (24) | 331 (21) | <.0001 | <.0001 | <.0001 | <.0001 |
| Yes | 379 | 140 (37) | 101 (27) | 138 (36) | ||||
| Involvement of 3 or more nodal areas | ||||||||
| No | 265 | 106 (40) | 73 (28) | 86 (32) | <.0001 | .3 | .0009 | .2 |
| Yes | 1680 | 899 (54) | 398 (24) | 383 (23) | ||||
| Elevated ESR‡ | ||||||||
| No | 703 | 420 (60) | 158 (22) | 125 (18) | <.0001 | .2 | <.0001 | .1 |
| Yes | 1239 | 583 (47) | 313 (25) | 343 (28) | ||||
| IPS§ | ||||||||
| 0-2 | 1207 | 668 (55) | 289 (24) | 250 (21) | <.0001 | <.0001 | <.0001 | .007 |
| 3-7 | 731 | 333 (46) | 180 (25) | 218 (30) | ||||
| HL subtype|| | ||||||||
| Classical HL | 1179 | 624 (53) | 261 (22) | 294 (25) | .1 | .2 | ||
| Nodular lymphocyte-predominant HL | 65 | 41 (63) | 13 (20) | 11 (17) |
| . | N= . | DS 1-2 (%) . | DS 3 (%) . | DS 4 (%) . | Univariate P, DS 3-4 vs 1-2 . | Multivariate P, DS 3-4 vs 1-2* . | Univariate P, DS 4 vs 1-3 . | Multivariate P, DS 4 vs 1-3* . |
|---|---|---|---|---|---|---|---|---|
| Age at registration | ||||||||
| 18-44 y | 1535 | 760 (50) | 390 (25) | 385 (25) | .0002 | .02 | .05 | |
| 45-60 y | 410 | 245 (60) | 81 (20) | 84 (20) | ||||
| Sex | ||||||||
| Female | 761 | 376 (49) | 197 (26) | 188 (25) | .1 | .6 | ||
| Male | 1184 | 629 (53) | 274 (23) | 281 (24) | ||||
| Performance status | ||||||||
| ECOG = 0 | 1151 | 633 (55) | 268 (23) | 250 (22) | .0004 | .9 | .004 | |
| ECOG > 0 | 794 | 372 (47) | 203 (26) | 219 (28) | ||||
| Clinical stage | ||||||||
| II | 282 | 82 (29) | 102 (36) | 98 (35) | <.0001 | .5 | <.0001 | .1 |
| III | 955 | 565 (59) | 215 (23) | 175 (18) | ||||
| IV | 708 | 358 (51) | 154 (22) | 196 (28) | ||||
| B symptoms | ||||||||
| No | 704 | 431 (61) | 149 (21) | 124 (18) | <.0001 | .3 | <.0001 | .2 |
| Yes | 1241 | 574 (46) | 322 (26) | 345 (28) | ||||
| Large mediastinal mass† | ||||||||
| No | 1383 | 838 (61) | 277 (20) | 268 (19) | <.0001 | <.0001 | <.0001 | <.0001 |
| Yes | 561 | 167 (30) | 194 (35) | 200 (36) | ||||
| Extranodal involvement | ||||||||
| No | 1566 | 865 (55) | 370 (24) | 331 (21) | <.0001 | <.0001 | <.0001 | <.0001 |
| Yes | 379 | 140 (37) | 101 (27) | 138 (36) | ||||
| Involvement of 3 or more nodal areas | ||||||||
| No | 265 | 106 (40) | 73 (28) | 86 (32) | <.0001 | .3 | .0009 | .2 |
| Yes | 1680 | 899 (54) | 398 (24) | 383 (23) | ||||
| Elevated ESR‡ | ||||||||
| No | 703 | 420 (60) | 158 (22) | 125 (18) | <.0001 | .2 | <.0001 | .1 |
| Yes | 1239 | 583 (47) | 313 (25) | 343 (28) | ||||
| IPS§ | ||||||||
| 0-2 | 1207 | 668 (55) | 289 (24) | 250 (21) | <.0001 | <.0001 | <.0001 | .007 |
| 3-7 | 731 | 333 (46) | 180 (25) | 218 (30) | ||||
| HL subtype|| | ||||||||
| Classical HL | 1179 | 624 (53) | 261 (22) | 294 (25) | .1 | .2 | ||
| Nodular lymphocyte-predominant HL | 65 | 41 (63) | 13 (20) | 11 (17) |
Data are n (row percentage) unless otherwise indicated.
ECOG, Eastern Cooperative Oncology Group; ESR, erythrocyte sedimentation rate.
Including all factors with univariate P < .001; N = 1934 due to exclusion of patients with any missing factor.
Missing in 1 patient.
Missing in 3 patients.
Missing in 7 patients.
Missing in 701 patients.